Publications by authors named "G Arcari"
Cefiderocol (FDC), a siderophore-cephalosporin conjugate, is the newest option for treating infection with carbapenem-resistant gram-negative bacteria. We identified a novel mechanism contributing to decreased FDC susceptibility in Klebsiella pneumoniae clinical isolates. The mechanism involves 2 coresident plasmids: pKpQIL, carrying variants of bla carbapenemase gene, and pKPN, carrying the ferric citrate transport (FEC) system.
View Article and Find Full Text PDFIntroduction: The genus is assuming greater clinical relevance among infections caused by also because of its intrinsic and acquired resistance to last-resort antibiotics. However, despite having been known and studied for over 50 years, genomics and taxonomy of the genus are currently undergoing a deep rearrangement. In this study we aim to outline and characterized the species.
View Article and Find Full Text PDFArticle Synopsis
- Carbapenemase-producing bacteria, particularly KPC-3-producing sequence type (ST) 512, pose a significant global health threat, with increasing resistance to advanced treatments like ceftazidime/avibactam (CZA).
- This study analyzed three isolates from a single patient over 78 days, including two that originated from a liver abscess, focusing on their antimicrobial resistance and genetic characteristics.
- The final isolate, hmv-318Kp, demonstrated CZA resistance and a hypermucoviscous phenotype due to specific genetic mutations, indicating an evolution of this strain in terms of infectivity and resistance mechanisms.
Carbapenem resistance is a serious public health threat, causing numerous deaths annually primarily due to healthcare-associated infections. To face this menace, surveillance programs in high-risk patients are becoming a widespread practice. Here we report the performance of the combined use of a recently approved commercial multiplex real-time PCR assay (REALQUALITY Carba-Screen kit) with conventional phenotypic screening.
View Article and Find Full Text PDFIn February 2022, a critically ill patient colonized with a carbapenem-resistant K. pneumoniae producing KPC-3 and VIM-1 carbapenemases was hospitalized for SARS-CoV-2 in the intensive care unit of Policlinico Umberto I hospital in Rome, Italy. During 95 days of hospitalization, ceftazidime/avibactam, meropenem/vaborbactam, and cefiderocol were administered consecutively to treat 3 respiratory tract infections sustained by different bacterial agents.
View Article and Find Full Text PDF